Stroke remains a leading cause of death and disability worldwide, profoundly affecting millions of people and their families annually. Among the most common risk factors is carotid artery stenosis\u2014the narrowing of the arteries that supply the brain with oxygen-rich blood. Severe narrowing significantly increases the risk of ischemic stroke, where a blocked artery deprives brain tissue of vital oxygen and nutrients, leading to cell death and long-term neurological deficits.<\/p>\n
Despite decades of research, there was no clear consensus on the most effective treatment combination for patients with significant carotid narrowing who had not yet suffered a stroke. Traditional approaches included intensive medical management (controlling blood pressure, cholesterol, and lifestyle) and surgical methods like endarterectomy or stenting. Until recently, it was unclear whether adding stenting to high-level medical management would further improve stroke prevention in these patients.<\/p>\n
To answer this critical question, clinicians and researchers worldwide collaborated on the CREST-2 clinical trial, involving over 2,400 patients across major centers, including University of Utah Health. CREST-2 was specifically designed to evaluate whether an endovascular stent, placed alongside state-of-the-art medical therapy, could further reduce the risk of stroke.<\/p>\n
Medical management in the study was comprehensive: patients received “gold standard” medications for cholesterol and blood pressure, paired with regular lifestyle coaching focused on healthy diet, exercise, and behavior modification. Half of the participants were also randomly assigned to undergo carotid artery stenting.<\/p>\n
The results of CREST-2 represent a significant advancement. Even compared to rigorous medical therapy alone, the addition of carotid stenting led to a sharp reduction in the risk of a first stroke. Specifically, in patients who received both stenting and intensive medical management, the stroke rate over a four-year follow-up period was nearly halved<\/b> compared to those receiving only medical treatment. This substantial benefit surprised many clinicians, as modern medical therapy\u2014especially aggressive risk-factor control\u2014was previously thought to have reached its maximum potential.<\/p>\n Stroke is one of the most difficult public health challenges, causing deep personal, social, and economic pressure. Globally, it is a primary cause of long-term disability, placing a heavy burden on patients, caregivers, and healthcare systems. Therefore, effective prevention strategies are a priority for clinicians and policymakers. More effective treatment will significantly reduce these factors and alleviate the pressure on overburdened healthcare systems.<\/p>\n Stroke prevention remains a primary focus of clinical research, especially amidst aging populations and the prevalence of risk factors like diabetes and hypertension. The CREST-2 study shows how combining innovative procedural techniques with aggressive medical care can achieve results previously thought unattainable. Future research will continue to optimize patient selection, minimize procedural risks, and integrate next-generation medications and imaging technologies into cardiovascular care.<\/p>\nWhy These Findings Matter<\/span><\/h3>\n
Future Outlook<\/span><\/h3>\n